{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:04Z","timestamp":1761871204650,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clml.2017.09.009","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T16:32:57Z","timestamp":1505925177000},"page":"812-818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward B.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany J.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0256-1146","authenticated-orcid":false,"given":"Arun","family":"Kanmanthareddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T.","family":"Silberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.09.009_bib1","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2017.09.009_bib2","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.009_bib3","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/0959-8049(92)90018-W","article-title":"The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group","volume":"28A","author":"Cosset","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2017.09.009_bib4","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin's disease: international prognostic factors project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.009_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early-stage Hodgkin's lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.009_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1600-0609.2005.00458.x","article-title":"Report from the Rockefeller Foundation sponsored international workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy","volume":"75","author":"Mauch","year":"2005","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.clml.2017.09.009_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clml.2015.11.006","article-title":"Trends in use of radiation therapy for Hodgkin lymphoma from 2000 to 2012 on the basis of the National Cancer Data Base","volume":"16","author":"Goyal","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2017.09.009_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.2014.58.7543","article-title":"Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base","volume":"33","author":"Olszewski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.009_bib9","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"year":"1997","series-title":"AJCC Cancer Staging Manual","key":"10.1016\/j.clml.2017.09.009_bib11"},{"year":"2002","series-title":"AJCC Cancer Staging Manual","author":"Greene","key":"10.1016\/j.clml.2017.09.009_bib12"},{"key":"10.1016\/j.clml.2017.09.009_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jclinepi.2014.09.010","article-title":"A\u00a0systematic review identifies valid comorbidity indices derived from administrative health data","volume":"68","author":"Yurkovich","year":"2015","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2017.09.009_bib15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2017.09.009_bib16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2017.09.009_bib17","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"Boll","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.009_bib18","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"Boll","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.009_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.09.009_bib20","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","article-title":"How can outcomes be improved for older patients with Hodgkin lymphoma?","volume":"31","author":"Evens","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.009_bib21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A\u00a0retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.009_bib22","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-07-0927","article-title":"Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin's disease","volume":"14","author":"Provencio","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.09.009_bib23","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.ejca.2010.02.010","article-title":"Mortality is persistently increased in Hodgkin's lymphoma survivors","volume":"46","author":"Kiserud","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2017.09.009_bib24","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.009_bib25","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.009_bib26","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.09.009_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.2011.08713.x","article-title":"Review of the cardiac long-term effects of therapy for Hodgkin lymphoma","volume":"154","author":"Ng","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.09.009_bib28","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jnci\/djp147","article-title":"Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma","volume":"101","author":"De Bruin","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2017.09.009_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0272-5231(03)00126-6","article-title":"Pulmonary complications of radiation therapy","volume":"25","author":"Abratt","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.clml.2017.09.009_bib30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ajh.24272","article-title":"Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Ansell","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.09.009_bib31","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.009_bib32","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","volume":"23","author":"Meyer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.009_bib33","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/cncr.23081","article-title":"Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma","volume":"110","author":"Hodgson","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.09.009_bib34","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.009_bib35","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.009_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/asheducation-2005.1.245","article-title":"Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy","author":"Bartlett","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2017.09.009_bib37","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2016-03-699090","article-title":"Bleomycin for older patients: less is more","volume":"127","author":"Moskowitz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.009_bib38","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.09.009_bib39","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"Boll","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.009_bib40","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/annonc\/mdv256","article-title":"The new therapeutical scenario of Hodgkin lymphoma","volume":"26","author":"Stathis","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.09.009_bib41","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.009_bib42","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2012-01-402792","article-title":"Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma","volume":"119","author":"Kasamon","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.009_bib43","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2012-01-405456","article-title":"Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma","volume":"119","author":"Younes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.009_bib44","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood.V122.21.3054.3054","article-title":"German Hodgkin Study Group phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older Hodgkin lymphoma patients","volume":"122","author":"Boll","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:49Z","timestamp":1761870709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017309709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S2152265017309709"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}